Showing 1961-1970 of 2105 results for "".
- Phase 2 Clinical Trial Initiated for Bryostatin Treatment of Alzheimer Diseasehttps://practicalneurology.com/news/phase-2-clinical-trial-initiated-for-bryostatin-treatment-of-alzheimer-disease/2469281/Researchers will evaluate the long-term therapeutic effect of bryostatin-1 (Neurotrope, New York, NY) for Alzheimer disease (AD) in a new phase 2 clinical study (NCT02221947). An estimated 10
- Blood Test May Help Predict Disease Progression in Individuals with Multiple Sclerosishttps://practicalneurology.com/news/blood-test-may-help-predict-disease-progression-in-individuals-with-multiple-sclerosis/2469268/A study published in Neurology shows that a blood test may help predict worsening of multiple sclerosis (MS) likely to occur within the next year. The test can detect a neurofilament light (NfL) cha
- New Social Networking Platform for the Multiple Sclerosis Communityhttps://practicalneurology.com/news/new-social-networking-platform-for-the-multiple-sclerosis-community/2469254/A new free anonymous AI-powered social networking and navigation platform, BelongMS (Belong.Life, New York, NY), has been launched for individuals with multiple sclerosis (MS), caregivers, and healthcare professionals. The app can be downloaded for Android and iOS. The new app follows t
- Higher Rates of COVID-19 Infection and Death for People With Parkinson Diseasehttps://practicalneurology.com/news/higher-rates-of-covid-19-infection-and-death-for-people-with-parkinson-disease/2469246/A paper accepted for publication in Movement Disorders suggests that people with Parkinson disease (PD) with longer disease duration (mean 12.7 years) may be more susceptible to infection with the SARS-CoV2 virus (COVID-19). Individual
- Risdiplam Resulted in Sitting Without Support for 5 Seconds by Month 12 for Infants with SMAhttps://practicalneurology.com/news/risdiplam-resulted-in-sitting-without-support-for-5-seconds-by-month-12-for-infants-with-sma/2469243/At the 1-year point of the Firefish part 2 (NCT02913482), a pivotal global study evaluating risdiplam (Genentech, San Francisco, CA), 29% (12/41; P<.0001) of infants with spinal muscular a
- FDA Approves Selumetinib for Children with Neurofibromatosis Type 1https://practicalneurology.com/news/fda-approves-selumetinib-for-children-with-neurofibromatosis-type-1/2469227/The Food and Drug Administration (FDA) approved selumetinib (Koselugo; AstraZeneca, Wilmington, DE) for the treatment of children age 2 years or more who have neurofibromatosis type 1 (NF1). Selumetinib, a kinase inhibitor, is approved for treatment of symptomatic inoperable plexiform neurofibrom
- Long-Term Exposure to Air Pollution and Rate of Cognitive Declinehttps://practicalneurology.com/news/long-term-exposure-to-air-pollution-and-rate-of-cognitive-decline/2469226/In a study published in Neurology researchers found an association of air pollution levels with cognitive impairment and decline in 1 of 2 large groups but not both. Both groups were ethnically and racially diverse and lived in the Northern Manhattan area of New York City. Participant's resid
- Rimegepant, Recently Approved for Acute Migraine Treatment, Now Available to Prescribe Via Telemedicinehttps://practicalneurology.com/news/rimegepant-recently-approved-for-acute-migraine-treatment-now-available-to-prescribe-via-telemedicine/2469221/Rimegepant (Nurtec; Biohaven, New Haven, CT), which was recently approved for acute treatment of migraine, is now available to be prescribed via a telemedicine platform (Cove, New York, NY). This is especially important in this unprecedented time of decreased access to routine health care, d
- FDA Authorizes Prescription Digital Therapeutic for Chronic Insomniahttps://practicalneurology.com/news/fda-authorizes-prescription-digital-therapeutic-for-chronic-insomnia/2469211/The Food and Drug Administration (FDA) has granted authorization for a prescription digital therapeutic (PDT) (Somryst, Pear Therapeutics, Boston, MA) intended for treating individuals age 22 years or more with chronic insomnia. The therapy is a 9-week PDT that can be used on a mo
- FDA Approves Ozanimod for Relapsing Multiple Sclerosishttps://practicalneurology.com/news/fda-approves-ozanimod-for-relapsing-multiple-sclerosis/2469208/The Food and Drug Administration (FDA) approved ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.